Conjugate of insulin and vitamin B12 for oral delivery
Compositions containing a therapeutic peptide covalently linked to Vitamin B 12 at the 5′-hydroxyl group of the ribose moiety of α-ligand are described. The length of the linkage is optimized so that the biological activity of both the Vitamin B 12 and the therapeutic peptide is maintained. Therapeutic peptide includes insulin, PYY, NPY and GLP-1. Attachment to Vitamin B 12 provides uptake of the therapeutic peptide from the digestive tract and longer residence time.
1. An oral delivery conjugate comprising vitamin B 12 coupled to a therapeutically active insulin via the LysB29 of insulin covalently attached to a mono-, di-, or tri-carboxylic acid derivative or the primary (5′) hydroxyl group of the ribose moiety of vitamin B 12 , the conjugate exhibiting at least 80% or more of the therapeutic activity of native insulin when the conjugate is administered orally.
2. The oral delivery conjugate of claim 1 , wherein the insulin is human insulin.
3. The oral delivery conjugate of claim 1 , wherein the covalent attachment is via a coupling agent.
4. The oral delivery conjugate of claim 3 , wherein the coupling agent provides a carbamate-linked conjugate.
5. The oral delivery conjugate of claim 4 , wherein the coupling agent is selected from the group consisting of N,N′-carbonyldiimidazole (CDI), 1,3-diisopropyl-carbodiimide (DIPC), 2-halo-1-alkyl-pyridinium halides (Mukaiyama reagents), 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (EDC), propane phosphonic acid cyclic anhydride (PP ACA) and phenyl dichlorophosphates.
6. The oral delivery conjugate of claim 5 , wherein the coupling agent is N,N′-carbonyldiimidazole (CDI).
7. The oral delivery conjugate of claim 3 , wherein the conjugate further comprises spacer units comprising polyethylene glycol monomers.
8. A pharmaceutical composition comprising the oral delivery conjugate of claim 1 and a pharmaceutically acceptable carrier.
9. The composition of claim 8 , further comprising Intrinsic Factor.
10. The composition of claim 9 , wherein the Intrinsic Factor is a human Intrinsic Factor.
11. A pharmaceutical composition, comprising:
an oral delivery form of insulin comprising vitamin B 12 covalently coupled to insulin, wherein the covalent coupling is between a mono-, di-, or tri-carboxylic acid derivative or the primary (5′) hydroxyl group of the ribose moiety of vitamin B 12 and LysB29 of insulin; and a pharmaceutically acceptable carrier suitable for oral delivery, wherein the oral delivery form of insulin retains about 80% or more of the biological activity of native insulin when the oral delivery form is administered to a mammal.
12. A method for treating diabetes mellitus, comprising orally administering to a patient in need thereof an amount of the pharmaceutical composition of claim 11 sufficient to lower blood glucose concentration in said patient, thereby treating the diabetes mellitus.
13. The method of claim 12 , wherein the pharmaceutical composition is in an oral delivery form selected from the group consisting of a capsule, a tablet, an emulsion, a colloidal dispersion, an elixir, a gel and a paste.
14. A kit comprising the pharmaceutical composition of claim 11 and an instruction sheet for oral administration.